(Q36945100)

17 August 2017

1 reference

title

Reflecting on type 2 diabetes prevention: more questions than answers! (English)

1 reference

17 August 2017

1 reference

Rosenstock J

1

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Diabetes, Obesity and Metabolism

17 August 2017

published in

1 reference

17 August 2017

volume

9 Suppl 1

1 reference

17 August 2017

page(s)

3-11

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

The DREAM trial – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00768.X

10.1111/J.1463-1326.2007.00768.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference